Trial
NCT04630353
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hookipa Biotech GmbH
Collaborators
—
Condition
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
Intervention
HB-201 IV
Why stopped
Sponsor decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-12